Regulator of G protein signaling 9 (RGS9)

Regulator of G protein signaling 9 (RGS9) is an enzyme of the RGS family that acts as a GTPase-activating protein (GAP), accelerating the deactivation of G protein alpha subunits to terminate G protein-coupled receptor (GPCR) signaling. It exists in two major isoforms—RGS9-1, primarily in retinal photoreceptors (rods and cones), crucial for rapid recovery of the phototransduction response, and RGS9-2, mainly in the brain's basal ganglia, where it modulates dopamine and opioid receptor signaling, impacting behaviors and responses to drugs like opioids. Mutations in RGS9 can cause bradyopsia (abnormally slow visual adaptation), and irregularities in its activity or regulation have been linked to altered drug tolerance and motor function. Although not a current, direct therapeutic target for approved drugs, RGS9 is involved in key signaling pathways with emerging interest for disorders of vision, movement, and opioid tolerance[1][2][3][5][7].

Other names

Regulator of G-protein signalling 9RGS9PERRSRGS9LMGC26458MGC111763regulator of G protein signalling 9regulator of G protein signalling 9Lregulator of G-protein signaling 9LPERRS1

Increases GTPase activity of Gα subunits, accelerates their inactivation, terminates GPCR signaling, modulates dopamine and opioid receptor signaling[2][3].